News
Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...
Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...
The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...
Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...
Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...
The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...
2d
Zacks Investment Research on MSNNovartis Beats on Q2 Earnings and Sales, CFO Retires, Stock DownSwiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...
Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC 1. Novartis is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results